Compare FPI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | MLYS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.2M | 3.1B |
| IPO Year | 2014 | 2023 |
| Metric | FPI | MLYS |
|---|---|---|
| Price | $9.72 | $37.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $47.33 |
| AVG Volume (30 Days) | 543.5K | ★ 1.5M |
| Earning Date | 10-29-2025 | 02-11-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 296.76 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $52,990,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $8.24 |
| 52 Week High | $12.87 | $47.65 |
| Indicator | FPI | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 43.16 |
| Support Level | $9.73 | $36.50 |
| Resistance Level | $9.87 | $38.23 |
| Average True Range (ATR) | 0.16 | 1.68 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 5.17 | 41.96 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.